Merck & Co., Inc. MRK
147.18 USD -0.87 (-0.59%)
At closeNov 12, 2026, 4:30 AM EST
148.58 +1.40 +0.95%
Pre-market · Nov 12, 4:30 AM ET
145.30 Day range 147.61
90.90 52-week range 156.92
- YTD
- +39.83%
- 1 year
- +60.94%
News
247wallst.com Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year Every one of these drugmakers is staring down a patent cliff, and that looming drop in sales is exactly why their dividends pay what they do. Which one carries the most risk, and which one rewards…
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
benzinga.com 'Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko'- Endpoints News https://endpoints.news/merck-kgaa-lands-fda-nod-for-joint-tumor-drug-it-licensed-from-abbisko/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
businesswire.com FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a…
gurufocus.com Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinic
benzinga.com Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet Efinopegdutide demonstrated a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis versus placebo at 52 weeksMeaningful improvements…
businesswire.com Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial…
zacks.com INVA or MRK: Which Is the Better Value Stock Right Now? Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value…
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
zacks.com MRK's 2027 Outlook Challenging, Long-Term Prospects Promising Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.
247wallst.com Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap Two men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who…
defenseworld.net Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC Asset One Wealth Management LLC boosted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 55.2% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The…
zacks.com Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold? MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…
defenseworld.net Merck & Co., Inc. $MRK Stock Acquired by Compass Financial Management LLC Compass Financial Management LLC lifted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 256.3% during the undefined quarter, according to its most recent disclosure with the Securities…
zacks.com MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last? Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.
defenseworld.net Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange…
benzinga.com Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care…
benzinga.com Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155 Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.- benzinga.com Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026 Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxisNew data include Phase 3 subgroup analyses and…
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175 JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $165 to $175.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
benzinga.com RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140 RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $145 to $140.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
benzinga.com Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171 Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.
benzinga.com Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027 Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com 8 Of 11 Sectors Rise Thursday As Defensives Lead Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…- benzinga.com Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 analyst estimate. Raises FY2026 sales outlook from $66.300 billion-$67.300 billion to $66.800…
- benzinga.com Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y) Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830…
benzinga.com Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate Merck & Co (NYSE:MRK) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.08 by 19.71 percent. This is a 3.49 percent decrease over earnings of $2.58 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Merck Endometrial Cancer Studies Show Significant Survival Gains Merck reports positive Phase 3 data for Keytruda and sac-TMT in endometrial cancer, showing significant survival gains at ESMO 2026.- benzinga.com Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet…
benzinga.com Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who…- benzinga.com Barclays Maintains Overweight on Merck & Co, Raises Price Target to $180 Barclays analyst Emily Field maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $180.
benzinga.com BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit BioNTech and DualityBio report modest Phase 3 breast cancer survival gains alongside higher lung toxicity, limiting overall patient benefit.
benzinga.com Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna’s stock went on a wild ride last week that included a data leak and a dramatic tale from a social media influencer.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Moderna Stock Slides Again Friday: What's Going On? Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.- benzinga.com Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42% Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected…
benzinga.com Why Is Moderna Stock Sinking Thursday? Moderna stock plummeted 25% following an alleged ESMO 2026 abstract leak showing lower-than-expected melanoma vaccine Phase 3 efficacy.